Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Sep 9 - Sep 14
Next steps: FDA decision (REDEFINE-1 & 2) expected late 2026 REDEFINE-11 (2.4/2.4 mg) readout in H1 2027 Higher-dose Phase 3 initiation planned H2 2026 Why It Matters: The obesity market is now a high-efficacy battleground, with GLP-1 and dual incretin therapies redefining standards of care
Do not rinse off
Can reconstituted peptides be frozen for longer-term storage
Be wary of providers that prescribe GLP-1s without thorough evaluation of your medical history, current medications, and contraindications
Avoid high-fat, fried, or rich foods
US$ 25.02
US$ 29.72
US$ 26.07
US$ 27.15
US$ 25.44
US$ 23.68
:max_bytes(150000):strip_icc():focal(710x110:712x112)/FDA-Updates-Ozempi-Label-Amid-Concerns-Over-Intestinal-Blockages-Linked-to-Semaglutide-Based-Drugs-092923-c374c02352e2400ea820da6d0cf2abc5.jpg)
US$ 22.51
